Power to the pathologist

INIFY® Prostate Screening is an AI-powered tool that provides pathologists with valuable decision support when identifying cancer in prostate biopsies. Exploring the advantages of today’s digital technology in whole new ways, and drawing on the very latest breakthroughs in deep learning, INIFY Prostate Screening empowers pathologists faced with today’s ever-increasing workload. It makes room for smarter, more accurate and faster decisions, is proven to be robust across different labs and scanners, and is adaptable to different workflows and user needs. INIFY Prostate Screening builds on the resilient foundation of innovation, technical know-how and professionalism that has been a trademark of ContextVision for the last 30 years.
INIFY® is a registered trademark of ContextVision AB

Power to the pathologist

INIFY® Prostate Screening is an AI-powered tool that provides pathologists with valuable decision support when identifying cancer in prostate biopsies. Exploring the advantages of today’s digital technology in whole new ways, and drawing on the very latest breakthroughs in deep learning, INIFY Prostate Screening empowers pathologists faced with today’s ever-increasing workload. It makes room for smarter, more accurate and faster decisions, is proven to be robust across different labs and scanners, and is adaptable to different workflows and user needs. INIFY Prostate Screening builds on the resilient foundation of innovation, technical know-how and professionalism that has been a trademark of ContextVision for the last 30 years.
INIFY® is a registered trademark of ContextVision AB
2020-06-29
We are proud to announce that INIFY® Prostate Screening has been granted CE mark status, and is now available for routine clinical use within the European Union.
Read the pressrelease

Upload your images for prediction – and get ready to be impressed!

 Use your own images to experience how INIFY® Prostate Screening powers up the pathologist's workflow.
Read more
INIFY® Podcast
In this episode, ContextVision's product manager Kristian Eurén explains the first of INIFY® Prostate Screening's superpowers: FAST. Subscribe to the podcast for more insights into the superpowers of INIFY.

00:46 Pre-processed, pre-analyzed slides speed up workflow
01:15 The viewer’s time-saving features
01:43 Smart annotation tools
02:05 Pre-sorted slides
02:23 Synchronized IHC slides and HE slides
02:36 Can pathologists correct the results?
03:07 Developed in sync with pathologists
03:32 Feedback from users
04:49 More about INIFY® 
CONTEXTVISION PODCAST
Podcast: How is AI revolutionizing digital pathology?

INIFY® Prostate Screening’s superpowers to rely on!

Smart
An algorithm is only as smart as its underlying training data. The predicting AI-based engine in INIFY Prostate Screening is built on deep learning algorithms that are meticulously trained.
Read more
Accurate
For real diagnostic confidence, accuracy is everything, and this is where we truly shine.
Read more
Robust
INIFY Prostate Screening’s algorithms stand up impressively to known differences between labs, enabling a plug-and-play approach. 
Read more
FAST
INIFY Prostate Screening is designed to help pathologists make the most of their valuable time.
 Read more 
ADAPTABLE
Our experienced specialists have been working closely together with pathologists from all over the world, creating tools that can be attuned to diverse clinical workflows and user needs. 
Read more
RESILIENT
Innovation, technical know-how and professionalism – these are the cornerstones of ContextVision’s enduring market leadership for the last 30 years.
Read more

What is INIFY Prostate Screening?

INIFY Prostate Screening is an AI-based and CE-marked decision support tool that suggests and outlines suspected cancer areas in digital H&E whole-slide images of prostate biopsy samples.

MasterAnnotation™ is a standardized procedure for generating close-to-ground-truth training data, patented by ContextVision. Patent US 10,572,996.
Learn more

One out of seven will be diagnosed with prostate cancer

Handling of prostate biopsies makes up an increasing amount of workload for today's pathology labs. Here, powerful decision support tools – such as INIFY Prostate Screening – have the potential to save valuable time for the pathologist, while ensuring a more objective, consistent and accurate evaluation of the biopsies.
Read more

MasterAnnotation™ – for accurate, reliable performance

The INIFY algorithms are trained on data from our MasterAnnotation method – a unique and patented innovation developed by ContextVision.
MasterAnnotation is our standardized procedure for generating training data. Briefly, a high-resolution multiplex immunofluorescence overlay is used to generate a precise annotation – an augmented ground truth – for the development and optimization of the INIFY algorithms.
In 2019, the MasterAnnotation method was granted patent protection by the U.S. Patent and Trademark Office (USPTO) – ContextVision’s first patent in the digital pathology field; patent US 10,572,996
A prototype version of the product has been used daily for two years in our fully digital pathology workflow here in Catania, and I can testify that it is really easy to use, saves time and helps highlight suspicious areas for cancer.
Dr. Filippo Fraggetta, Chief Pathologist
Cannizzaro Hospital, Italy
Newsletter

Get the latest on product updates, events and company news

Sign up

Pioneering the frontiers of image analysis

INIFY Prostate Screening builds on the strong foundation of innovation, technical know-how and professionalism that has been a trademark of ContextVision for the last 30 years. Today, our state-of-the-art solutions for medical imaging are used in over 300,000 systems worldwide.
To www.contextvision.com
Events

Meet the INIFY team

We look forward to demonstrating INIFY Prostate Screening, answering your questions and sharing ideas about the future at these upcoming venues:

The VIRtUAL
ESP/IAP 2020 Congress

6–8 December 2020

32nd Congress of the ESP and XXXIII International Congress of the IAP

32nd Congress of the ESP and XXXIII International Congress of the IAP: 

A Vision for the Future
Read more